Corcept Therapeutics Incorporated (CORT)
Return on equity (ROE)
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Net income | US$ in thousands | 139,733 | 106,140 | 101,418 | 112,512 | 106,011 |
| Total stockholders’ equity | US$ in thousands | 679,589 | 506,705 | 501,842 | 375,806 | 523,338 |
| ROE | 20.56% | 20.95% | 20.21% | 29.94% | 20.26% |
December 31, 2024 calculation
ROE = Net income ÷ Total stockholders’ equity
= $139,733K ÷ $679,589K
= 20.56%
Based on the data provided, Corcept Therapeutics Incorporated's return on equity (ROE) has shown a positive trend over the years, indicating efficient use of shareholders' equity to generate profits.
In December 31, 2020, the ROE was 20.26%, which increased to 29.94% by December 31, 2021, reflecting a significant improvement in profitability. However, there was a slight decrease in ROE to 20.21% by December 31, 2022, before rebounding to 20.95% by December 31, 2023.
By December 31, 2024, the ROE stood at 20.56%, indicating consistent performance in utilizing equity to generate returns for shareholders.
Overall, Corcept Therapeutics has demonstrated a healthy ROE performance, with fluctuations in profitability over the years but maintaining a strong return relative to the shareholders' equity invested in the company. The company should continue to monitor and enhance its ROE to ensure sustainable growth and value creation for its shareholders.
Peer comparison
Dec 31, 2024